Development, Optimization, and Comprehensive Characterization of Eudragit RL 100-Based Amisulpride Microspheres for Sustained Oral Drug Delivery: Process Parameter Optimization and Comparative InVitro Evaluation
International Journal of Drug Delivery Technology · 25.04.2026 · 16 (19s)
DOI: 10.25258/ijddt.16.19s.53 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.04.2026. Verfasst von Aadil Bokada und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Amisulpride is an atypical antipsychotic drug characterized by poor aqueous solubility and variable oral bioavailability, necessitating the development of an effective controlled-release delivery system. The present study reports the development and optimization of amisulpride-loaded Eudragit RL 100 microspheres incorporated into a microsphere-based tablet for sustained oral drug delivery. Microspheres were prepared using the solvent evaporation technique. The critical formulation parameters, including drug-to-polymer ratio, internal phase volume, stabilizer concentration, stirring speed, and stirring time, were systematically optimized. Preformulation studies confirmed drug purity and compatibility through melting point determination, UV spectrophotometric analysis (λmax 252 nm), and FT-IR studies. The optimized formulation (drug: polymer ratio of 1:10, 10 mL DCM, 1% PVA, 1500 rpm, and 90 min) exhibited high entrapment efficiency (90.94 ± 2.35%), percentage yield (89.62 ± 1.36%), and drug content (86.94 ± 2.25%), with a statistically significant improvement (p < 0.05) compared to the preliminary batches. SEM analysis revealed spherical and uniform microspheres with acceptable micromeritic properties. In vitro drug release studies demonstrated sustained release behavior, achieving 89.67 ± 1.26% drug release over 6 h, significantly higher than that of the marketed formulation (51.47 ± 1.37%, p < 0.05). Drug release kinetics followed the Higuchi model, indicating diffusion-controlled release, as further supported by the Korsmeyer–Peppas analysis, which suggested non-Fickian transport. The microspheres were successfully compressed into tablets, which exhibited acceptable hardness (3.3 kg/cm2), low friability (0.18%), and uniform drug content (90.45 ± 2.35%). Stability studies confirmed no significant changes in the physicochemical properties over 30 days. In summary, the developed microsphere-based tablet demonstrated enhanced encapsulation efficiency, controlled drug release, and improved performance compared to conventional formulations, highlighting its potential as an effective sustained-release oral drug delivery system for amisulpride.
Zitieren
APA
Bokada, A., Patani, D. M., Nangha, D. B., Chaudhari, P., Patel, A., Sonawane, H., & Upadhyay, D. S. (2026). Development, Optimization, and Comprehensive Characterization of Eudragit RL 100-Based Amisulpride Microspheres for Sustained Oral Drug Delivery: Process Parameter Optimization and Comparative InVitro Evaluation. International Journal of Drug Delivery Technology, 16(19s). https://doi.org/10.25258/ijddt.16.19s.53
Vancouver
Bokada A, Patani DM, Nangha DB, Chaudhari P, Patel A, Sonawane H, et al. Development, Optimization, and Comprehensive Characterization of Eudragit RL 100-Based Amisulpride Microspheres for Sustained Oral Drug Delivery: Process Parameter Optimization and Comparative InVitro Evaluation. International Journal of Drug Delivery Technology. 2026;16(19s). doi:10.25258/ijddt.16.19s.53
BibTeX
@article{Bokada2026,
author = {Bokada, Aadil and Patani, Dr Mital and Nangha, Dr Bhavna and Chaudhari, Prathamesh and Patel, Ajay and Sonawane, Harshal and Upadhyay, Dr Siddhi},
title = {Development, Optimization, and Comprehensive Characterization of Eudragit RL 100-Based Amisulpride Microspheres for Sustained Oral Drug Delivery: Process Parameter Optimization and Comparative InVitro Evaluation},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {19s},
doi = {10.25258/ijddt.16.19s.53}
}
EUVIMED